| Literature DB >> 28955427 |
Temitope W Ladi-Akinyemi1, Ikeoluwa Ajayi2.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is common and often goes undetected and undiagnosed until the disease is well advanced and kidney failure is imminent. It is estimated that approximately 36 million Nigerians suffer from different stages of CKD, as one in seven Nigerians has kidney disease.Entities:
Mesh:
Year: 2017 PMID: 28955427 PMCID: PMC5610290 DOI: 10.4314/mmj.v29i2.17
Source DB: PubMed Journal: Malawi Med J ISSN: 1995-7262 Impact factor: 0.875
Sociodemographic characteristics of cases and controls
| Variable | Subjects | Total n (%) | Test statistic | P-value | |
| Cases n (%) | Controls n (%) | ||||
| 20 to 29 | 35 (23.3) | 98 (32.8) | 131 (29.5) | X2 = 5.510 | 0.357 |
| 30 to 39 | 42 (28.0) | 73 (24.3) | 115 (25.6) | ||
| 40 to 49 | 28 (18.7) | 57 (19.0) | 88 (18.9) | ||
| 50 to 59 | 27 (18.0) | 38 (12.7) | 65 (14.4) | ||
| ≥ 60 | 18(12.0) | 34(11.3) | 52 (11.6) | ||
| Mean age ± SD | 40.6 ± 14.4 | 38.6 ± 15.8 | t = 1.660 | 0.098 | |
| Range | 16 to 77 | 14 to 88 | |||
| Male | 90 (60.0) | 212 (70.7) | 302 (67.1) | X2 = 5.155 | 0.023 |
| Female | 60 (40.0) | 88 (29.3) | 148 (32.9) | ||
| None | 30 (20.0) | 24 (8.0) | 54 (12.0) | ||
| Primary | 29 (19.3) | 59 (19.7) | 88 (19.6) | X2 = 14.054 | 0.003 |
| Secondary | 62 (41.3) | 151(50.3) | 213 (47.3) | ||
| Tertiary | 29 (19.3) | 66 (22.0) | 95 (21.1) | ||
| Student | 24 (16.0) | 62 (20.7) | 86 (19.1) | ||
| Unemployed | 8 (5.3) | 18 (6.0) | 26 (5.8) | X2 = 3.651 | 0.455 |
| Unskilled | 74 (49.3) | 145 (48.3) | 219 (48.7) | ||
| Semi-skilled | 28 (18.7) | 56 (18.7) | 84 (18.7) | ||
| Skilled | 16 (10.7) | 19 (6.3) | 35 (7.8) | ||
| Single | 34 (22.7) | 106 (35.3) | 140 (31.1) | ||
| Married | 108 (72.0) | 181 (60.3) | 289 (64.2) | X2 = 10.519 | 0.015 |
| Divorced | 3 (2.0) | 1 (0.3) | 4 (0.9) | ||
| Widowed | 5 (3.3) | 12 (4.0) | 17 (3.8) | ||
SD = standard deviation;
= statistically significant (P ≤ 0.05)
Lifestyle factors among cases and controls
| Variable | Subjects | Total n (%) | Test | P-value | |
| Cases n (%) | Controls n (%) | ||||
| Yes | 19 (12.7) | 35 (11.7) | 54 (12.0) | X2 = 0.095 | 0.758 |
| No | 13 (87.3) | 265 (88.3) | 396 (88.0) | ||
| Mean cigarettes per | 6.6 ± 4.8 | 2.0 ± 1.2 | t = 5.361 | 0.001 | |
| Range, cigarettes per | 1 to 20 | 1 to 6 | |||
| Yes | 52 (34.7) | 82 (27.3) | 134 (29.8) | X2 = 2.572 | 0.109 |
| No | 98 (65.3) | 218 (72.7) | 316 (70.2) | ||
| Mean drinks per day ± | 3.7 ± 4.1 | 1.9 ± 1.2 | t = 4.083 | 0.004 | |
| Range, drinks per day | 1 to 15 | 1 to 4 | |||
| Yes | 130 (86.7) | 126 (42.0) | 256 (56.9) | X2 = 82.443 | 0.001 |
| No | 20 (13.3) | 174 (58.0) | 194 (43.1) | ||
| Yes | 20 (13.4) | 2 (0.7) | 22 (4.9) | X2 = 34.544 | 0.001 |
| No | 130 (86.7) | 298 (99.3) | 428 (95.1) | ||
SD = standard deviation;
= statistically significant (P ≤ 0.05)
Medical conditions among cases and controls
| Variable | Subjects | Total n (%) | Test statistic | P-value | |
| Cases n (%) | Controls n (%) | ||||
| Normal | 20 (13.3) | 159 (53.0) | 179 (39.8) | X2 = 65.683 | < 0.001 |
| Elevated | 130 (86.7) | 141 (47.0) | 271 (60.2) | ||
| Mean SBP ± SD | 167.0 ± 40.0 | 130.3 ± 30.5 | 142.5 ± 38.0 | t = 10.476 | < 0.001 |
| Normal | 38(25.3) | 202(67.3) | 240(53.3) | X2 = 70.875 | < 0.001 |
| Elevated | 112(74.7) | 98(32.7) | 210(46.7) | ||
| Mean DBP ± SD | 105±28.6 | 81±18.8 | 89.0±28.2 | t = 10.106 | < 0.001 |
| Yes | 91(60.7) | 40(13.3) | 131(29.1) | X2 = 108.721 | < 0.001 |
| No | 59(39.3) | 260(97.3) | 319(70.9) | ||
| Yes | 16(10.7) | 8(2.7) | 24(5.3) | X2 = 12.696 | 0.001 |
| No | 134(89.3) | 292(97.3) | 426(94.7) | ||
| Yes | 10(6.7) | 5(1.7) | 15(3.3) | X2 = 7.759 | 0.005 |
| No | 140(93.3) | 295(98.3) | 435(96.7) | ||
| Yes | 6(4.0) | 1(0.3) | 7(1.6) | X2 = 8.779 | 0.006 |
| No | 144(96.0) | 299(99.7) | 443(98.4) | ||
| Yes | 11(7.3) | 2(0.7) | 13(2.9) | X2 = 15.842 | < 0.001 |
| No | 139(92.7) | 298(99.3) | 437(97.1) | ||
SD = standard deviation;
= statistically significant (P ≤ 0.05)
Medications and dietary habits among cases and controls
| Variable | Subjects | Total n (%) | Test statistic | P-value | |
| Cases n (%) | Controls n (%) | ||||
| Yes | 94 (62.7) | 53 (11.0) | 127 (28.2) | X2 = 132.083 | < 0.001 |
| No | 56 (37.3) | 267 (89.0) | 323 (71.8) | ||
| Yes | 96 (64.0) | 31 (10.3) | 127 (28.2) | X2 = 192.177 | < 0.001 |
| No | 54 (36.0) | 269 (89.7) | 323 (71.8) | ||
| Yes | 92 (61.3) | 51 (17.0) | 143 (31.8) | X2 = 90.820 | < 0.001 |
| No | 58 (38.7) | 248 (83.0) | 307 (68.2) | ||
| Yes | 3 (2.0) | 1 (0.3) | 4 (0.9) | X2 = 3.153 | 0.076 |
| No | 147 (98.0) | 299 (99.7) | 446 (99.1) | ||
NSAIDs = non-steroidal anti-inflammatory drugs;
= statistically significant (P ≤ 0.05)